›› 2019, Vol. 31 ›› Issue (5): 730-736.DOI: 10.3969/j.issn.1004-1524.2019.05.08

• Animal Science • Previous Articles     Next Articles

Clinical efficacy and mechanism prediction of Difutongrusan in treatment of bovine mastitis

BAI Dongdong, LI Xinpu, YANG Feng, LUO Jinyin, WANG Xurong, LI Hongsheng*   

  1. Key Laboratory of Veterinary Pharmaceutical Discovery, Ministry of Agriculture and Rural Affairs, Key Laboratory of New Animal Drug Project of Gansu Province, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou Gansu 730050, China
  • Received:2018-11-03 Online:2019-05-25 Published:2019-05-23

Abstract: To study the antibacterial activity, clinical effect and mechanism of Difutongrusan in the treatment of bovine mastitis. The antibacterial activities of Difutongrusan against the main pathogens of bovine mastitis were determined by the method of micro broth first, then the cows with mastitis were treated to observe the cure rate and the effective rate. Finally, BATMAN, STRING, Cytoscape databases and softwares were used to analyze the mechanism of treatment of bovine mastitis by Difutongrusan. The results showed that the MIC/MBC of Difutongrusan on Staphylococcus agalactiae was 1.52 mg·mL-1, the MIC on Escherichia coli and Staphylococcus aureus was 25 mg·mL-1, and the MBC was twice as high as the MIC; The clinical cure rate of bovine mastitis was 63.16% and the effective rate was 89.47%. A total of 21 active compounds were selected from Difutongrusan, with 173 corresponding targets and 5 pivotal targets. The results indicated that Difutongrusan could have high antibacterial activity in vitro against the main pathogenic bacteria of bovine mastitis, and the clinical efficacy could be definite, which may be mainly through the pivotal target NT5E, IL8, ESR1, PIK3CA and PIK3CB to treat bovine mastitis.

Key words: Difutongrusan, bovine mastitis, antimicrobial activity, clinical efficacy, mechanism of action

CLC Number: